Pillar 1: Product Development
Product Description
ProductLife Group
-
Country/Region:France
-
On CPHI since:2023
-
Certificates:1
-
Employees:1000 - 4999
Categories
Specifications
ProductLife Group
-
Country/Region:France
-
On CPHI since:2023
-
Certificates:1
-
Employees:1000 - 4999
More Products from ProductLife Group (2)
-
Product Pillar 2: Life Cycle Management
Central and Local Outsourcing Operating ModelPromotional Materials
Product Marketing Authorization and Life Cycle Management
Pre Marketing Approval Support
Interaction with Global Health Authorities
Health-Care Compliance – France
Regulatory Intelligence & Strategy Building -
Product Pillar 3: Strategy & Digital
Our services for vigilance & Safety:EU QPPV and LPPV/LSO
Pharmacovigilance Consulting
Case Management
Regulatory Medical Writing
Medical Information
Literature Watch
Cosmetovigilance
Medical Devices and IVD Vigilance
ProductLife Group resources (4)
-
News Product Development Trends for a Changing Market: Breakfast Session Bulletin
Throughout CPHI North America 2023, several Breakfast Sessions were held to start the day off right with a complimentary breakfast and a networking and learning session for our attendees. With insightful presentations from industry experts and partners, the CPHI North America Breakfast Sessions had something for everyone looking to fill their brains and their stomachs.
-
Whitepaper ARTIFICIAL INTELLIGENCE (AI) IN PHARMACOVIGILANCE: DO WE REALLY NEED IT…?
There seems to be a lack of clarity about the meaning of terms such as “artificial intelligence (AI)”, “machine learning (ML)”, “data science (DS)” and “office automation (OA)”, which should not be used interchangeably. Pharmacovigilance (PV) represents a very interesting field in this regard, since it poses some unique technical challenges. For example, the “signal to noise ratio” and the “quality of the information” are very different in reports from clinical trials and in information coming from social networks, smartphone apps or smartwatches, and therefore require different approaches. Case processing, moreover, requires a mix of administrative and repetitive tasks (e.g. data cleaning and form filling) and tasks that require a high level of experience and specialization (e.g. medical reviews and signal detection). For more information, contact us. -
News CPHI North America 2023 – From the Floor
Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center!
-
Whitepaper DIGITAL HEALTH TECHNOLOGY (DHT) IN DRUG DEVELOPMENT
EMA Regulatory Science to 2025 enounces five strategic goals for regulatory science. EMA seeks to help regulatory science develop and use it to ensure advances in knowledge translation in a timely way into new, safe, and effective treatments for patients. The vision for human medicines is to underpin its mission of protecting human health, and EMA must catalyze and enable regulatory science and innovation to translate into patient access in evolving healthcare systems. To this end, five strategic goals are proposed. Each is associated with a set of core recommendations and their supporting actions.
1.Catalysing the integration of science and technology in medicines development
2.Driving collaborative evidence generation — improving the scientific quality of evaluations
3.Advancing patient-centered access to medicines in partnership with healthcare systems
Contact us to get more information.
